Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348400 | 0.89 | FKBP1A (0.45) | FKBP1AACEACE2KLK5ELANE | |
| SCHEMBL15373369 | 0.85 | POLB (0.44) | FKBP1AACEACE2KLK5ELANE | |
| SCHEMBL8046113 | 0.84 | KLK5 (0.51) | FKBP1AACEKLK5ELANE | |
| SCHEMBL14202917 | 0.84 | KLK5 (0.51) | FKBP1AACEKLK5ELANE | |
| SCHEMBL12969779 | 0.82 | KCNH2 (0.51) | FKBP1AACEACE2KLK5ELANE | |
| SCHEMBL16317405 | 0.81 | ELANE (0.43) | ACEACE2ELANECTSL | |
| SCHEMBL7539145 | 0.81 | CMA1 (0.46) | FKBP1AACEACE2KLK5 | |
| SCHEMBL1300341 | 0.81 | ACE (0.51) | ACEACE2ELANE | |
| SCHEMBL159043 | 0.81 | ACE (0.51) | ACEACE2ELANE | |
| SCHEMBL806133 | 0.81 | ACE (0.51) | ACEACE2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | FKBP1A 1684/4885ACE 3012/4885ACE2 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.